NCT06480565View on ClinicalTrials.gov

A Phase 1/2 Trial of ADI-270 in ccRCC

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 12, 2024

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2027

Conditions
Clear Cell Renal Cell Carcinoma
Interventions
DRUG

ADI-270

Anti-CD70 CAR-T

DRUG

Fludarabine

Chemotherapy for Lymphodepeletion

DRUG

Cyclophosphamide

Chemotherapy for Lymphodepletion

Trial Locations (1)

94065

Adicet Clinical Trials, Redwood City

Sponsors
All Listed Sponsors
lead

Adicet Therapeutics

INDUSTRY

NCT06480565 - A Phase 1/2 Trial of ADI-270 in ccRCC | Biotech Hunter | Biotech Hunter